Lux Biosciences

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Lux Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 5 completed later-stage tilt upper quartile by trial count

Lux Biosciences: 7 sponsored US clinical trials, none currently recruiting.

Lux Biosciences sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 6 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Panuveitis, with 2 trials.

Upper-quartile sponsor footprint

Lux Biosciences sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 3

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

NCT01243983
COMPLETED Phase 1

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734
TERMINATED Phase 3

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
TERMINATED Phase 3

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642
COMPLETED Phase 3

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404885
COMPLETED Phase 3

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404612
COMPLETED Phase 3

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 6

Therapeutic Areas

Panuveitis 2
Keratoconjunctivitis Sicca 1
Uveitis, Intermediate 1
Uveitis, Anterior 1
Uveitis, Posterior 1

How the Lux Biosciences archive is shaped

7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).

Phase mix: 6 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Panuveitis (2 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Lux Biosciences: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Lux Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Lux Biosciences3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Lux Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Lux Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Lux Biosciences page

7 registered trials is a research-attention snapshot, not an endorsement of Lux Biosciences or any single study.

  • None of Lux Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Panuveitis is the condition Lux Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Panuveitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Lux Biosciences pipeline card: 7 registered trials from official public datasets.Report a data error.